Healthcare & Medical Devices Global On demand · 24-48h

Global Influenza A-B Virus Detection Kit Market Strategic Research Report

Global Influenza A-B Virus Detection Kit Market Strategic Re…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Influenza A-B Virus Detection Kit Market
$1.58B2025
5.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Antigen Test, Nucleic Acid Amplification Testing, Others

By Application: Hospital, Clinic, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: BD, Abbott, Quidel, Actim, Denka, Roche, Thermo Fisher Scientific, Meridian Bioscience, Sekisui Diagnostics, Princeton BioMeditech, Access Bio, Response Biomedical, Guangzhou Wondfo Biotech, Jiangsu Bioperfectus Technologies, Hangzhou Biotest Biotech, Wantai BioPharm, Daan Gene, Kehua Bio-Engineering, Zhuhai Encode Medical Engineering

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 134 pages
Market size 2025
$1.58B
Billion USD
Forecast CAGR
5.1%
2025-2032
Forecast 2032
$2.2B
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global Influenza A-B Virus Detection Kit market size is predicted to grow from US$ 1,578 million in 2025 to US$ 2,217 million in 2032; it is expected to grow at a CAGR of 5.1% from 2026 to 2032.

The Influenza A-B Virus Detection Kit is an in vitro diagnostic product designed to detect Influenza A and B virus antigens or nucleic acids from respiratory specimens. It primarily utilizes immunochromatographic assays, fluorescent immunoassays, or real-time quantitative PCR technology, suitable for hospital laboratories, public health institutions, and home testing scenarios. Key upstream raw materials include high-specificity antibodies or primer-probe sets, antigen controls, enzyme reagents, buffers, protein stabilizers, nitrocellulose membranes, and injection-molded casings, with advanced versions incorporating electronic reading modules. Downstream customers mainly include hospitals, community healthcare centers, third-party testing labs, pharmacies, and the home diagnostic market. In 2024, the global production capacity of Influenza A-B virus detection kits is estimated at 420 million tests, with sales around 340 million tests, an average price of USD 4.5 per test, and an industry gross margin of approximately 62%. The market continues to grow steadily, driven by seasonal influenza outbreaks, enhanced respiratory disease surveillance, and increasing consumer demand for home-use diagnostic solutions.

At present, the market for Influenza A-B virus detection kits is experiencing steady expansion, driven by the cyclical outbreaks of seasonal influenza, reinforced public health policies, and the rising awareness of preventive healthcare. Many countries have integrated influenza testing into routine respiratory infection screening programs, and since the enhancement of epidemic prevention systems, combined detection of influenza, COVID-19, and RSV has emerged as a new growth driver. The rapid penetration of medical institutions and retail pharmacy channels has also significantly increased the accessibility and adoption of rapid test kits in primary care and home-use scenarios.

In the coming years, continuous improvements in immunochromatographic technology and the advancement of digital diagnostic platforms will further enhance sensitivity, specificity, and result visualization. Fluorescent immunoassay, molecular point-of-care testing (POCT), and multiplex detection will remain the core innovation directions, offering differentiated solutions for various application settings. Meanwhile, leading manufacturers are actively investing in smart reader systems and cloud-based data connectivity to improve testing efficiency and public health surveillance. On the policy front, governments worldwide are encouraging early screening for respiratory infections and promoting home health management, providing sustained support for market growth.

Nevertheless, the industry still faces notable challenges. Product homogeneity and price competition continue to compress profit margins for many manufacturers. Fluctuating raw material costs and international trade barriers threaten supply chain stability, especially for small and medium-sized enterprises. Furthermore, complex and time-consuming registration procedures across regions pose compliance and financial challenges. At the same time, consumers’ growing expectations for accuracy and convenience are driving faster product upgrades. Overall, despite structural pressures, the market retains solid long-term potential, supported by continuous technological innovation, stronger brand differentiation, and global market expansion.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Influenza A-B Virus Detection Kit market?

What factors are driving Influenza A-B Virus Detection Kit market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Influenza A-B Virus Detection Kit market opportunities vary by end market size?

How does Influenza A-B Virus Detection Kit break out by Type, by Application?

This report presents a comprehensive overview of the global Influenza A-B Virus Detection Kit market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Antigen Test
  • Nucleic Acid Amplification Testing
  • Others

Segment by Detection Principle

  • Immunochromatography
  • Colloidal Gold Method
  • Others

Segment by Sample Type

  • Nasal Swab
  • Throat Swab
  • Nasopharyngeal Swab
  • Others

Segment by Packaging

  • Single-Test Pack
  • Bulk Pack

Segment by Application

  • Hospital
  • Clinic
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Influenza A-B Virus Detection Kit market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital, Clinic, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Influenza A-B Virus Detection Kit Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.58B
2025
Forecast
$2.2B
2032
CAGR
5.1%
2025–2032
Области
5
global
Key companies
BDAbbottQuidelActimDenkaRocheThermo Fisher ScientificMeridian Bioscience
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Antigen TestNucleic Acid Amplification TestingOthers
By Application
HospitalClinicOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Antigen Test
  • 3.1.3 Nucleic Acid Amplification Testing
  • 3.1.4 Others
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital
  • 4.1.3 Clinic
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 BD
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Abbott
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Quidel
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Actim
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Denka
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Roche
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Thermo Fisher Scientific
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Meridian Bioscience
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Sekisui Diagnostics
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Princeton BioMeditech
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Access Bio
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Response Biomedical
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Guangzhou Wondfo Biotech
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Jiangsu Bioperfectus Technologies
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Hangzhou Biotest Biotech
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Wantai BioPharm
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Daan Gene
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Kehua Bio-Engineering
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Zhuhai Encode Medical Engineering
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Influenza A-B Virus Detection Kit market?
The global Influenza A-B Virus Detection Kit market is estimated at US$ 1.58 billion in 2025 (base year) and is projected to reach US$ 2.22 billion by 2032.
What is the forecast CAGR for the Influenza A-B Virus Detection Kit market?
The market is expected to grow at a CAGR of 5.1% from 2026 to 2032, expanding from US$ 1.58 billion in 2025 to US$ 2.22 billion in 2032, roughly 1.4 times its base-year value.
What is Influenza A-B Virus Detection Kit?
The Influenza A-B Virus Detection Kit is an in vitro diagnostic product designed to detect Influenza A and B virus antigens or nucleic acids from respiratory specimens. It primarily utilizes immunochromatographic assays, fluorescent immunoassays, or real-time quantitative PCR technology, suitable for hospital laboratories, public health institutions, and home testing scenarios.
What are the main segments of the Influenza A-B Virus Detection Kit market by type?
By type, the market is segmented into Antigen Test, Nucleic Acid Amplification Testing and Others.
Which applications drive demand in the Influenza A-B Virus Detection Kit market?
Key applications covered include Hospital, Clinic and Others.
Who are the key players in the Influenza A-B Virus Detection Kit market?
Key players profiled include BD, Abbott, Quidel, Actim, Denka, Roche, Thermo Fisher Scientific and Meridian Bioscience, among 19 companies covered in total.
Which regions and countries are covered for Influenza A-B Virus Detection Kit?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Influenza A-B Virus Detection Kit market?
At present, the market for Influenza A-B virus detection kits is experiencing steady expansion, driven by the cyclical outbreaks of seasonal influenza, reinforced public health policies, and the rising awareness of preventive healthcare.
What challenges does the Influenza A-B Virus Detection Kit market face?
Nevertheless, the industry still faces notable challenges.
Who should buy the Influenza A-B Virus Detection Kit market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Influenza A-B Virus Detection Kit market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.